Potassium oxonate is a uricase inhibitor, affecting the phosphorylation of 5-FU into 5-fluorouridine-5'-monophosphate differently from allopurinol, both in cell-free extracts and intact cells. When administered orally alongside 5-FU (2 mg/kg) to Yoshida sarcoma-bearing rats, oxonic acid (10 mg/kg) specifically inhibits the conversion of 5-FU into its phosphorylated form and its incorporation into RNA in the intestines but not in tumor or bone marrow tissues[1]. Additionally, an oxonic acid diet raises plasma uric acid levels by 80-90 micromol/L, with an observed increase in blood pressure only in hyperuricemic rats subjected to a 5/6 nephrectomy (18 mmHg)[2].
Potassium Oxonate/氧嗪酸钾 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Sprague-Dawley rats
Hyperuricemia model
Oral
4%
Six consecutive weeks
Establish a hyperuricemia model to study the therapeutic effects of Sulforaphane on hyperuricemia.
J Adv Res. 2023 Oct;52:19-28
Kunming mice
Hyperuricemia mouse model
Oral gavage
900 mg/kg
Once daily for two weeks
To evaluate the effect of Beta-Alanine on urate levels and XOD expression in hyperuricemic mice. Beta-Alanine significantly reduced blood and urine urate levels and decreased XOD expression.
Redox Biol. 2025 Apr;81:103546
KK-Ay mice
Type 2 diabetes with hyperuricemia model
Peritoneal injection
250 mg/kg
Daily for 8 weeks
Induced hyperuricemia model to study the effect of Empagliflozin on hyperuricemia
搜索
